Drug resistance in pancreatic cancer: New player caught in act
Open Access
- 1 February 2019
- journal article
- editorial
- Published by Elsevier in EBioMedicine
- Vol. 40, 39-40
Abstract
No abstract availableFunding Information
- ssociazione Italiana Ricerca sul Cancro (IG 18790, IG 17177)
This publication has 7 references indexed in Scilit:
- Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolitesEBioMedicine, 2019
- Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in EuropePancreatology, 2019
- Pancreatic cancer stem cells: A state or an entity?Seminars in Cancer Biology, 2018
- Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trialThe Lancet Gastroenterology & Hepatology, 2018
- Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell deathOncology Reports, 2018
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- Biology and management of pancreatic cancer.2007